LRMR Larimar Therapeutics Inc

Price (delayed)

$3.865

Market cap

$401.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.39

Enterprise value

$313.32M

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 40
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 1

Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. ...

Highlights
LRMR's equity is down by 19% since the previous quarter but it is up by 6% year-on-year
LRMR's quick ratio is down by 12% year-on-year but it is up by 9% since the previous quarter
The EPS has plunged by 85% YoY and by 9% from the previous quarter
The company's net income has shrunk by 73% YoY and by 4% QoQ

Key stats

What are the main financial stats of LRMR

LRMR stock price

How has the Larimar Therapeutics stock price performed over time
Intraday
1.18%
1 week
-1.65%
1 month
-7.54%
1 year
-12.95%
YTD
1.44%
QTD
26.72%

Financial performance

How have Larimar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$178.99M
Net income
-$172.61M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 73% YoY and by 4% QoQ
Larimar Therapeutics's operating income has shrunk by 65% YoY and by 3.8% QoQ

Price vs fundamentals

How does LRMR's price correlate with its fundamentals

Growth

What is Larimar Therapeutics's growth rate over time

Valuation

What is Larimar Therapeutics stock price valuation
P/E
N/A
P/B
3.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 85% YoY and by 9% from the previous quarter
LRMR's P/B is 56% above its 5-year quarterly average of 2.0 and 8% above its last 4 quarters average of 2.9
LRMR's equity is down by 19% since the previous quarter but it is up by 6% year-on-year

Efficiency

How efficient is Larimar Therapeutics business performance
LRMR's ROE has dropped by 118% year-on-year and by 2.5% since the previous quarter
The ROIC has plunged by 83% from the previous quarter
Larimar Therapeutics's ROA has plunged by 81% YoY

Dividends

What is LRMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LRMR.

Financial health

How did Larimar Therapeutics financials performed over time
LRMR's total liabilities is up by 26% year-on-year but it is down by 25% since the previous quarter
The total assets is down by 21% QoQ but it is up by 10% YoY
The debt is 96% less than the equity
LRMR's debt to equity has soared by 100% from the previous quarter
The debt has grown by 31% from the previous quarter and by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.